European Journal of Cancer
Volume 39, Issue 6 , Pages 801-807 , April 2003

Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)

  • I. Fichtner

      Affiliations

    • Max-Delbrueck-Center for Molecular Medicine, Experimental Pharmacology, Robert-Roessle-Str. 10, D-13092 Berlin-Buch, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-30-94-06-22-95; fax: +49-30-94-06-38-23
    • ,
  • M. Becker

      Affiliations

    • Max-Delbrueck-Center for Molecular Medicine, Experimental Pharmacology, Robert-Roessle-Str. 10, D-13092 Berlin-Buch, Germany
    • ,
  • J. Baumgart

      Affiliations

    • Medac GmbH, Theaterstr. 6, D-22880 Wedel, Germany

Received 1 June 2002 ,Revised 5 September 2002 ,Accepted 21 November 2002.

References 

  1. Feit PW, Rastrup-Andersen N. Studies on epoxide formation from (2S,3S)-Threitol 1,4-Bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-Epoxy-3,4-butanediol 4-Methanesulfonate. J. Med. Chem. 1970;13:1173–1175
  2. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br. J. Cancer. 1999;79:264–266
  3. Masding J, Sarkar TK, White WF, et al.  Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinomas. Obstet. Gynecol. 1990;97:342–351
  4. Gropp M, Meier W, Hepp H. Treosulfan as an effictive second-line therapy in ovarian cancer. Gynecol. Oncol. 1998;71:94–98
  5. Merkle E, Ackermann S, Beck EP, et al.  High-dose versus low-dose Cisplatin chemotherapy plus Treosulfan in epithelial ovarian carcinoma FIGO II-IV. Results of a prospective randomized trial. Onkologie. 2000;23:232–238
  6. Köpf-Maier P, Saß G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother. Pharmacol. 1992;31:103–110
  7. Köpf-Maier P, Saß G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother. Pharmacol. 1996;37:211–221
  8. Köpf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro. In vivo. 1998;12:275–288
  9. Neale MH, Myatt N, Cree IA, et al.  Combination chemotherapy for choroidal melanoma (ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside). Br. J. Cancer. 1999;79:1487–1493
  10. Neuber K, tom Dieck A, Blödorn-Schlicht N, et al.  Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Mel. Res. 1999;9:125–132
  11. Griskevicius L, Gaughan U, Nilsson C, et al. The myeloablative and immunosuppressive properties of treosulfan in mice, Proceedings 28th Annual Meeting of the European Group for Blood and Marrow Transplantation, March 24–27, 2002, Montreux, Switzerland (abstr. 603).
  12. Melchers I, Rzepka R, Meinel T. Immunosuppressive activity of low dose Treosulfan. Proceedings Joint Annual Meeting of Immunology, November 29–December 2, 2000, Duesseldorf (abstr. 1212).
  13. Ploemacher RE, Westerhof GR, Blokland I, et al.  Treosulfan as an alternative conditioning agent in bone marrow transplantation. Bone Marrow Transplant. 2000;25(Suppl. 1):141; (abstr. P421).
  14. Casper J, Knauf W, Steiner D, et al. Toxicity-reduced conditioning with Treosulfan and Fludarabine. Proceedings 43rd Annual Meeting of the American Society of Hematology, December 7–11, 2001, Orlando, Fl, (abstr. 786).
  15. Loeb V. Dihydroxybusulfan (NSC-39069) in chronic myelocytic leukaemia and miscelaneous malignant neoplasms. Cancer Chemother. Rep. 1964;42:39–43
  16. Topaly J, Fruehauf S, Ho AD, et al.  Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents (implications for pretransplant conditioning). Br. J. Cancer. 2002;86:1487–1493
  17. Meinhardt GH, Eppinger E, Jahrsdoerfer B. Treosulfan is an effective inducer of cell death in myeloma cells. Proceedings 43rd Annual Meeting of the American Society of Hematology, December 7–11, 2001, Orlando, Fl (abstr. 2692).
  18. Borgmann A, Baldy C, von Stackelberg A, et al.  Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr. Hematol. Oncol. 2000;17:635–650
  19. Harstrick A, Wilke H, Eberhardt W, et al.  A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie. 1996;19:153–156
  20. Scheulen ME, Hilger RA, Oberhoff C, et al.  Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin. Cancer Res. 2000;6:4209–4216
  21. Wagner HM, Baumgart J, Andreesen R, Reichle A. Tandem high-dose chemotherapy for advanced ovarian carcinoma (dose-escalation of treosulfan in combination with carboplatin and etoposide). Bone Marrow Transplant. 2000;26(Suppl. 1):33; (abstr. P33)
  22. Baynes, R.D., Parchment, R., Dansey, R.D., et al., High-dose melphalan, DTIC and treosulfan (MDT) and PBPCT in previously treated metastatic breast and ovarian cancer, Proceedings. 36th Annual Meeting of the American Society of Clinical Oncology, May 20–23, 2000, New Orleans. Louisiana (abstr. 585).
  23. Westerhof GR, Ploemacher RE, Boudewijn A, et al.  Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res. 2000;60:5470–5478

PII: S0959-8049(02)00767-0

doi: 10.1016/S0959-8049(02)00767-0

European Journal of Cancer
Volume 39, Issue 6 , Pages 801-807 , April 2003

Article Tools

* Image Usage & Resolution